Higher Doses of Thymosin Alpha-1 Boost Cancer Treatment Effectiveness in Melanoma
Increasing thymosin alpha-1 doses in combination with chemotherapy and interferon significantly improved anti-tumor effects against melanoma in mice.
Quick Facts
What This Study Found
Dose-escalation of thymosin alpha-1 in triple chemo-immunotherapy (cyclophosphamide + thymosin alpha-1 + interferon) produced dose-dependent increases in anti-tumor efficacy against B16 melanoma in mice.
Key Numbers
How They Did This
Animal study in C57BL/6 mice with B16 melanoma. Multiple thymosin alpha-1 doses were tested in combination with cyclophosphamide and low-dose interferon-alpha/beta. Tumor growth and immune cell activity were measured.
Why This Research Matters
Showing that thymosin alpha-1 has dose-dependent anti-tumor effects suggests the immune-boosting benefits increase with higher doses, which is important for optimizing cancer immunotherapy combinations.
The Bigger Picture
Cancer immunotherapy aims to enhance the immune system's ability to fight tumors. Thymosin alpha-1's dose-dependent immune enhancement in combination therapy demonstrates its potential as an immunotherapy adjuvant, a principle being explored in modern cancer treatment.
What This Study Doesn't Tell Us
Mouse melanoma model; results may not translate directly to human cancer. B16 is a specific melanoma model and results may vary with other cancer types. Toxicity of higher doses not extensively characterized.
Questions This Raises
- ?Is there a ceiling dose beyond which thymosin alpha-1 efficacy plateaus or toxicity appears?
- ?Would these results translate to human melanoma patients?
- ?Which immune cell populations are most affected by thymosin alpha-1 dose escalation?
Trust & Context
- Key Stat:
- Dose-dependent response Higher thymosin alpha-1 doses produced progressively greater anti-tumor effects when combined with chemotherapy and interferon
- Evidence Grade:
- Moderate evidence from a well-controlled animal study showing clear dose-response relationship, but limited to a single mouse cancer model.
- Study Age:
- Published in 1998. Thymosin alpha-1 has continued to be studied as an immunotherapy adjuvant, with clinical trials in various cancers.
- Original Title:
- High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
- Published In:
- Anticancer research, 18(5A), 3571-8 (1998)
- Authors:
- Pica, F(2), Fraschetti, M, Matteucci, C, Tuthill, C, Rasi, G
- Database ID:
- RPEP-00484
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How does thymosin alpha-1 fight cancer?
Thymosin alpha-1 boosts immune cells like natural killer cells and T-cells that can recognize and destroy cancer cells. Combined with chemotherapy that weakens the tumor, the enhanced immune response can more effectively control cancer growth.
Are higher doses always better?
In this study, higher thymosin alpha-1 doses produced better anti-tumor results. However, there are likely upper limits in humans where side effects could outweigh benefits. Clinical trials are needed to determine optimal dosing.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00484APA
Pica, F; Fraschetti, M; Matteucci, C; Tuthill, C; Rasi, G. (1998). High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.. Anticancer research, 18(5A), 3571-8.
MLA
Pica, F, et al. "High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.." Anticancer research, 1998.
RethinkPeptides
RethinkPeptides Research Database. "High doses of thymosin alpha 1 enhance the anti-tumor effica..." RPEP-00484. Retrieved from https://rethinkpeptides.com/research/pica-1998-high-doses-of-thymosin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.